| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $142,412,176 ) (Continued on the next page) |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA303334 | Context-specific pathway dependencies for nuclear envelope proteins in brain cancer | 000 | 1 | NIH | 6/25/2026 | $718,275 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK142741 | Structural Basis of Thermogenic Mitochondrial Respiratory Complexes Assembly | 000 | 2 | NIH | 4/6/2026 | $813,511 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK140171 | Cellular and Biochemical Pathways of Adipose Metabolism and Thermogenesis | 000 | 2 | NIH | 4/28/2026 | $844,198 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F31AI191729 | Deciphering the mechanisms regulating itaconate production and signaling in macrophages | 000 | 2 | NIH | 8/11/2026 | $48,521 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U10CA180794 | ECOG-ACRIN Network Group Statistics and Data Management Center | 002 | 12 | NIH | 7/15/2026 | $129,189 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U10CA180794 | ECOG-ACRIN Network Group Statistics and Data Management Center | 001 | 12 | NIH | 7/8/2026 | $8,287,023 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA284254 | Defining Therapeutically Targetable Regulators of Tumor-Intrinsic Immune Suppression in Glioblastoma | 001 | 4 | NIH | 4/16/2026 | $10,313 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA284254 | Defining Therapeutically Targetable Regulators of Tumor-Intrinsic Immune Suppression in Glioblastoma | 000 | 4 | NIH | 1/13/2026 | $92,813 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32CA298459 | Interrogating the role of IFNgamma in promoting metastasis and immune evasion of triple negative breast cancer | 000 | 2 | NIH | 7/31/2026 | $79,348 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279391 | Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | 001 | 3 | NIH | 4/16/2026 | $72,700 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279391 | Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy | 000 | 3 | NIH | 1/15/2026 | $654,298 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01HG014175 | Calling germline and mosaic variants from long genomic and RNA-seq reads | 000 | 2 | NIH | 8/13/2026 | $515,462 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA155010 | Personal tumor neoantigens for immunity against chronic lymphocytic leukemia | 000 | 15 | NIH | 1/27/2026 | $683,283 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | UG1CA233180 | NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care | 000 | 7 | NIH | 4/1/2026 | $997,843 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK078081 | Metabolic crosstalks in regulation of beta-cell stress response and adaptation | 000 | 14 | NIH | 3/2/2026 | $488,374 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA300092 | Mapping the epigenetic dynamics of prostate cancer progression: integrating liquid biopsies and single-cell epigenomics for early detection of lineage plasticity and clinical decision-making | 001 | 2 | NIH | 4/3/2026 | $201,524 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA300092 | Mapping the epigenetic dynamics of prostate cancer progression: integrating liquid biopsies and single-cell epigenomics for early detection of lineage plasticity and clinical decision-making | 000 | 2 | NIH | 3/23/2026 | $406,450 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R35CA197588 | Role of Phosphoinositides and Protein Kinases in the control of Cancer Metabolism | 000 | 10 | NIH | 7/21/2026 | $1,064,242 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA279221 | Dissecting Integrated Cellular Programs Promoting Platinum Resistance and Progression in Bladder Cancer | 000 | 3 | NIH | 3/27/2026 | $712,559 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA155010 | Personal tumor neoantigens for immunity against chronic lymphocytic leukemia | 001 | 15 | NIH | 4/16/2026 | $75,920 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK082889 | Transcriptional control and enhancer recruitment in mouse and human intestinal secretory differentiation | 000 | 14 | NIH | 2/26/2026 | $372,621 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA270040 | BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Cancer - a Multi-Site Randomized Controlled Trial | 000 | 4 | NIH | 8/6/2026 | $669,032 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | UG1HL069249 | BMT CTN Core - Dana-Farber Cancer Institute and MGH Consortium | 001 | 26 | NIH | 6/18/2026 | $252,257 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA300495 | Dissecting the impact of tumor-immune spatial interactions in mismatch-repair stratified colorectal cancers | 000 | 2 | NIH | 7/16/2026 | $170,641 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA269285 | Cyclin C-CDK8/19 kinases in development and in cancer | 000 | 5 | NIH | 4/17/2026 | $525,969 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32CA306146 | Elucidating the role of PATZ1 in MYCN-amplified neuroblastoma | 000 | 2 | NIH | 8/6/2026 | $81,580 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R35GM158220 | Empowering NMR Utilization in Mechanistic Biology: Extending Size Limits and Catalyzing Automation | 001 | 2 | NIH | 8/27/2026 | $94,462 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA097098 | Targeting the MUC1-C Oncoprotein in Triple-Negative Breast Cancer | 000 | 22 | NIH | 3/30/2026 | $454,678 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R35GM158220 | Empowering NMR Utilization in Mechanistic Biology: Extending Size Limits and Catalyzing Automation | 000 | 2 | NIH | 5/13/2026 | $489,500 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA286537 | Mechanism and functional consequences of dietary lipids in lineage specification and tumor growth in oncohistone gliomas | 001 | 3 | NIH | 4/13/2026 | $702,458 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R35CA305086 | New approaches to targeting cell cycle proteins for cancer treatment | 001 | 2 | NIH | 7/24/2026 | $855,249 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U54CA274516 | Radiation Oncology at the Interface of Pediatric Cancer Biology and Data Science | 001 | 4 | NIH | 9/2/2026 | $1,531,447 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F31CA301844 | Unraveling the Mechanisms of Neoantigen Vaccine-Induced Epitope Spreading | 000 | 2 | NIH | 6/10/2026 | $37,114 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99GM157510 | Revealing Cellular Determinants of LINE-1 Retrotransposition Outcomes | 000 | 2 | NIH | 7/29/2026 | $125,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R21CA307422 | Reprogramming tumor-associated macrophages with theranostic nanoparticles | 000 | 1 | NIH | 7/6/2026 | $454,109 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA307360 | Therapeutic vulnerabilities of ARID1A-mutant and -wildtype ovarian clear cell carcinoma | 000 | 1 | NIH | 8/20/2026 | $528,099 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R35HL183474 | Elucidating the Origins and Drivers of Clonal Dynamics in Hematopoiesis | 000 | 1 | NIH | 3/10/2026 | $445,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA299840 | Daily Step Count, Patient- Reported Outcomes, and Recurrence-Free Survival in Early Breast Cancer Survivors | 000 | 1 | NIH | 9/2/2026 | $168,960 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R13AR088535 | The Fourth International Merkel Cell Carcinoma Symposium | 002 | 1 | NIH | 4/24/2026 | $5,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R13AR088535 | The Fourth International Merkel Cell Carcinoma Symposium | 001 | 1 | NIH | 3/27/2026 | $5,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R13AR088535 | The Fourth International Merkel Cell Carcinoma Symposium | 000 | 1 | NIH | 3/9/2026 | $15,000 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA303520 | Flipping the Switch in Cell Cycle Control: Dissecting the Molecular Mechanisms Governing Wee1 Kinase transition from Cdk Inhibitor to Substrate | 000 | 1 | NIH | 6/12/2026 | $645,102 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA311335 | USP1 inhibitor-mediated reversal of PARP inhibitor resistance in ovarian cancer. | 000 | 1 | NIH | 6/12/2026 | $463,279 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA312809 | Defining epigenetic underpinnings of neuroendocrine lineage carcinomas | 000 | 1 | NIH | 6/30/2026 | $170,394 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32DK146509 | A small-molecule methyltransferase as a direct target of metformin | 001 | 1 | NIH | 2/27/2026 | $0 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | F32DK146509 | A small-molecule methyltransferase as a direct target of metformin | 000 | 1 | NIH | 2/27/2026 | $78,040 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01DK142783 | Niche regulation of gastric epithelial cell differentiation | 000 | 1 | NIH | 3/19/2026 | $740,581 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA315599 | Dissecting Oxygen Sensing and PTEN Loss in FDG/Fluciclovine Uptake as Markers of PSMA Radioligand Therapy Resistance | 000 | 1 | NIH | 8/24/2026 | $170,639 |
| | 2026 | 2026 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA316481 | TRIM28 Inhibition as a Synthetic Lethal Strategy for Small Cell Lung Cancers with NOTCH2-Inactivation | 000 | 1 | NIH | 8/24/2026 | $609,130 |
|
